DS 1062

Drug Profile

DS 1062

Alternative Names: DS 1062a; DS-1062

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer

Most Recent Events

  • 01 Jan 2018 Phase-I clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA and Japan (IV) (JapicCTI-173812) (NCT03401385) (Daiichi Sankyo pipeline, February 2018)
  • 13 Dec 2017 Pharmacodynamics data from preclinical trials in Solid tumours released by Daiichi Sankyo
  • 13 Dec 2017 Daiichi Sankyo plans clinical trials for Cancer (TROP2 associated)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top